Overview
CareFirst v. Amgen examines whether Amgen’s 2004 restructuring of a Roche license—described by the FTC as giving Amgen exclusive control over two pending etanercept applications—could affect competition before patents issued. The series follows prosecution control, priority, continuations, rival uncertainty, later patents and injunctions, HSR early termination, and Noerr-Pennington petitioning. Its central lesson is that commercial acquisition, patent status, government procedure, and antitrust effects are related but distinct. The FTC’s framework supports scrutiny of an independently significant exclusive acquisition while leaving market power, rival effects, private injury, patent validity, damages, liability, and the Fourth Circuit’s outcome unresolved.
Learning outcomes
- Exclusive control of a pending application may matter before issuance because it can shape future claims and rival expectations.
- The FTC distinguishes Amgen’s commercial acquisition from later USPTO prosecution and patent enforcement.
- HSR early termination ends a waiting-period process; it is not a legality finding, endorsement, or immunity certificate.
- The record supports a possible antitrust mechanism, not final findings on market power, injury, validity, liability, or appeal outcome.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
Why can a pending patent application matter to antitrust law?
A pending patent application can matter to antitrust law because exclusive control may shape future claims, preserve priority, support continuations, and make rival entry harder to predict.
What did Amgen’s 2004 restructuring change?
According to the FTC’s account, the 2004 restructuring changed a non-exclusive Roche license into Amgen’s exclusive control over the relevant patent family, two pending applications, and their prosecution.
Does early HSR termination mean a transaction is lawful?
No. Early HSR termination ends the statutory waiting-period process but is not a legality determination, endorsement, or bar to later antitrust scrutiny.
Does Noerr-Pennington protect the entire CareFirst v. Amgen transaction?
No. It may protect Amgen’s later USPTO prosecution and patent litigation as petitioning, but it does not automatically immunize the independently significant commercial acquisition.
What has CareFirst v. Amgen actually decided?
The reported district-court ruling allowed the acquisition-based theory to proceed and certified questions for interlocutory appeal; the supplied materials do not establish final liability or a Fourth Circuit merits decision.